BIRC5 and breast carcinoma: In identifying the key downstream mediators through which erbB3 contributes to chemoresistance, we found that elevated expression of erbB3 conferred paclitaxel resistance in erbB2+ breast cancer cells via PI-3 K/Akt-dependent upregulation of Survivin, a critical inhibitor of apoptosis [76].